FONT-SIZE Plus   Neg

VIVUS Says FDA Extends Qnexa PDUFA Date

VIVUS Inc. (VVUS) said Monday that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act date for its review of the Qnexa New Drug Application by three months from April 17 to July 17, 2012.

On April 4, following the FDA's request, VIVUS submitted the Qnexa Risk Evaluation and Mitigation Strategy, which was considered a major amendment to the NDA. The submission consisted of proposed REMS materials.

Since the receipt date was within three months of the user fee goal date, the FDA is extending the Prescription Drug User Fee Act date by three months to provide time for a full review of the submission, the company noted.

The Qnexa NDA seeks approval for the treatment of obesity, including weight loss and maintenance of weight loss for obese patients with weight-related co-morbidities such as hypertension, type 2 diabetes or dyslipidemia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Daimler AG were losing around 3 percent in the morning trading, after the German auto giant trimmed its forecast for fiscal 2016 revenues and unit sales, while it backed adjusted EBIT view. Meanwhile, in the third quarter, the company recorded higher earnings and revenues, with increased sales volumes. German software developer SAP SE reported Friday lower profit in its third quarter due to higher stock-based compensation expense. However, revenues were higher. All regions posted improved results. Citing the strong cloud performance, the company said it is confident to deliver a strong fourth quarter, and also raised its full-year 2016 operating profit and revenue outlook. Shares of Ericsson were declining around 3 percent in the early morning trading after the Swedish telecom operator reported Friday a loss in its third quarter as net sales were hurt by weaker demand for mobile broadband, especially in markets with weak macro-economic environment.
comments powered by Disqus
Follow RTT